Counsyl Files for Declaratory Judgment That It's Not Infringing Myriad's BRCA Patent Claims | GenomeWeb

NEW YORK (GenomeWeb News) – Counsyl, a company that provides carrier screening and genetic testing for inherited conditions, has taken the preemptive action of asking a California federal district court to determine that it wouldn't be infringing Myriad Genetics' patent claims on BRCA 1 and BRCA 2 genes if it were to offer testing on those genes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.